Cellectis suffered its worst day in two years on the Paris stock exchange on Monday. The 13% slump began when it became clear that a conference call held by Cellectis, Pfizer and Servier would do little more than clarify the roles of each party in their recently struck CAR-T collaboration.
While pharma may not have the carbon footprint of energy or heavy manufacturing, it has other connections to environment and climate issues. The way climate change will affect public health, for instance, is a growing topic in global "green" pharma discussions, as is prescription drug pollution in the environment.
San Diego biotech BioAtla is sharing its immuno-oncology assets with Pfizer in a deal worth up to $1 billion, mixing and matching technologies in hopes of hitting on a winning combination.
San Diego-based BioAtla has snagged a potential mega deal with Pfizer that seeks to combine conditionally active biologic (CAB) antibodies with proprietary antibody drug conjugate payloads as part of a deal worth a possible $1 billion to BioAtla.
Hillary Clinton is putting more heat on the pharma industry, laying out a new proposal to curb corporate tax inversions weeks after Pfizer announced that it would merge with Allergan to reap the benefits of a lower tax rate.
As Pfizer moves forward with its agreed-upon $160 billion merger with Allergan, analysts expect it to eventually part ways with its consumer health business. And when it does, it's got a potential buyer in Reckitt Benckiser.
Pfizer, whose 2011 sale of a huge R&D site in the U.K. has hardly been forgotten there, is planning to shut down another research center in the country, a move that will cost about 120 jobs.
Pfizer's decision to buy Allergan wasn't much of a surprise; the nominally Dublin-based Allergan was among the few buyout targets that could deliver CEO Ian Read's desired tax inversion.
Valneva reported positive Phase II results this week for its GlaxoSmithKline-partnered C. difficile vaccine candidate, saying the shot proved to be "highly immunogenic" while also offering a good safety and tolerability profile.
Now that would be some ad budget. Pfizer is already the biggest-budget pharma advertiser by far, but if the merger with Allergan clears its hurdles, a combined "Pfizergan" could become one of the biggest advertisers, period.